Questions About Funding, Text Of Tufts Study On Drug Costs 03/02/2015 by Intellectual Property Watch Leave a Comment The Union for Affordable Cancer Treatment has sent a letter to the author of a much-noted Tufts University (US) study that found high development costs for medicines, with copies to the university administration. The letter requests transparency on the funding of the study and the press conference announcing the results, as well as copies of the study itself, which the group says was not made public, along with details to justify the result.
WHO Board Recommends Extension Of Plan For Health Innovation, IP 03/02/2015 by William New and Catherine Saez, Intellectual Property Watch 1 Comment The World Health Organization Executive Board this week recommended the extension of an important strategy and plan of action on health, IP and innovation. It also set out steps to resolve questions over evaluation and review of the strategy and plan of action before the annual World Health Assembly in May.
WHO Sets Path For Completing Rules Of Engagement With Industry, Foundations 02/02/2015 by William New, Intellectual Property Watch Leave a Comment The World Health Organization Executive Board has set a way forward from now to the annual May World Health Assembly for addressing the sensitive issue of drafting a framework for engagement with “non-state actors,” such as industry, foundations, academics and other non-governmental stakeholders.
WHO Still Finding Its Way On Financing R&D For Diseases Affecting Poor Countries 02/02/2015 by Catherine Saez, Intellectual Property Watch Leave a Comment In search of sustainable innovation models for cures for diseases affecting primarily developing countries, with the Ebola epidemic as a new reminder of the necessity and urgency of the matter, the World Health Organization had tasked an expert working group with the search for solutions. Last week, the WHO Executive Board took note of the progress made so far.
Special Report: Will India Bend To US Pressure On IP Rights? 31/01/2015 by Patralekha Chatterjee for Intellectual Property Watch 5 Comments It is no secret that the United States has been scaling up pressure on India to adopt intellectual property measures similar to those common in the United States and the European Union. But to what extent does India’s new government led by the business-friendly Narendra Modi see eye to eye with US official position? Can India, the “pharmacy of the world”, resolve the friction between pharmaceutical patents and access to affordable medicines without putting off foreign investors? The vitriolic and polarising debate surrounding these questions has got a fresh lease of life following US President Barack Obama’s landmark three-day visit to India this week. While Indian and American business moguls are bullish about the future, Indian generic drug-makers as well as health activists within and outside India are deeply anxious about the shape of things to come
IP Rights Must Remain Distinct From Fake Medicines Policy At WHO, Members Warn 30/01/2015 by Catherine Saez, Intellectual Property Watch 1 Comment Intellectual property issues emerged at the World Health Organization Executive Board today as members discussed fake and substandard medicines, with some countries saying that the fight against such medicines should not serve as a pretext to enforce intellectual property rights and prevent access to safe generic medicines.
Antimicrobial Resistance, Budget, Reform Raise Debate At WHO Executive Board 30/01/2015 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Health Organization Executive Board this week has addressed the relationship between the UN agency and its funders and lobbyists, examined the budget for the next biennium, and looked at the issue of the growing resistance of bacteria to antibiotics. Image Credits: Flickr – NIAID
Gavi Receives Record-Breaking Financial Pledges For Vaccines 29/01/2015 by Catherine Saez, Intellectual Property Watch Leave a Comment Gavi, the Vaccine Alliance, boasted success this week as its biennial replenishment conference attracted US$ 7.5 billion in pledges, which is the organisation said is expected to allow 300 million additional children to be vaccinated in poor countries. The vaccine industry pledged support for “strong” immunisation programmes, while public health advocates called for significant price […]
New Proposal To Extend WHO Action Plan On Innovation, IP Rights 27/01/2015 by Catherine Saez, Intellectual Property Watch Leave a Comment At the World Health Organization Executive Board today, a group of countries tabled a proposal to extend the WHO plan of action on public health, innovation and intellectual property until 2022. Yesterday, the Executive Board took note of the Global Vaccine Action Plan while some countries remarked on issues of affordability and accessibility. And today, one of the key discussions of the week – on the engagement of WHO with lobbyists, donors, and other interested non-governmental parties – has begun.
Ebola, Reform High On WHO Executive Board Agenda This Week 26/01/2015 by Catherine Saez and William New, Intellectual Property Watch 1 Comment The World Health Organization Executive Board yesterday adopted a resolution on Ebola, on the eve of today’s opening of its 10-day meeting addressing a broad range of health issues, including several of relevance to the intellectual property and innovation community. Today, Italy requested that member states be involved in the setting of WHO guidelines, raising governance issues, while WHO Director General Margaret Chan called for strong health systems and reform to the WHO structure, and asked for room to move on WHO relations with industry.